SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is experiencing significant volatility as market sentiment fluctuates between excitement over its role in global AI infrastructure and frustration over recent stagnant price action compared to semiconductor peers. While community members are heavily debating the sustainability of the AI rally and the implications of broader sector rotation, many remain focused on the stock's potential for a breakout based on its dominant position in data center expansion and upcoming earnings.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing intense buying activity and high volume as investors react to confirmed purchase orders linked to Marvell Technologies and ongoing speculation about partnerships with major cloud hyperscalers. Community sentiment is overwhelmingly bullish, with many traders framing the recent price action as a structural breakout that is forcing short sellers to cover their positions.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is surging as investors cheer the semiconductor sector's broader AI momentum, heavily fueled by sympathy gains following a strong earnings report from Intel. While the community is actively debating whether this reflects sustainable demand or an overheating AI bubble, many are highlighting the rapid price expansion while navigating the volatility of a heavily shorted stock.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing a massive surge in market interest and investor sentiment following a significant earnings beat and strong forward guidance that surprised many who were bearish on the stock. The community is actively debating whether this movement is driven by a genuine fundamental turnaround and structural AI demand, or if it represents an overextended short squeeze that is susceptible to a sharp retracement.

Skillz, Inc. operates a mobile gaming platform that connects players in competition. It helps developers build franchises by enabling social competition in their games. Skillz hosts casual esports tournaments for mobile players worldwide. The company was founded by Andrew C Paradise and Casey Chafkin in 2012 and is headquartered in Las Vegas, NV.

Skillz Inc - Ordinary Shares - Class A

Skillz Inc

Skillz Inc is surging as investors react to a significant jury verdict awarding the company substantial damages in a lawsuit involving competitor Papaya Gaming. While the stock has seen extreme volatility and aggressive shorting, the community is intensely debating the potential for a major squeeze and whether the legal win provides long-term fundamental value.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is experiencing extreme volatility and intense community debate as investors weigh the stock's massive rally, driven by AI data center and power infrastructure narratives, against concerns over its financials and potential short-term exhaustion. While bulls highlight the company's GaN technology as a critical long-term play for AI energy efficiency, a vocal contingent of bears is actively shorting the stock, citing stretched valuations and the high probability of an equity offering.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is capturing significant attention as investors weigh the potential of its oral Wegovy pill against Eli Lilly's recent market entry, with the company's new AI partnership with OpenAI further fueling hopes for accelerated drug discovery. Despite recent share price volatility, the community is actively debating the stock's valuation, dividend yield, and the long-term impact of evolving GLP-1 competitive dynamics.

MaxLinear, Inc. engages in the provision of communications systems-on-chip (SoC) solutions used in broadband, mobile and wireline infrastructure, data center, and industrial and multi-market applications. Its products include cable broadband modems and gateways, wireline connectivity devices, radio frequency transceivers, fiber-optic modules, video set-top boxes and gateways, hybrid analog and digital televisions, direct broadcast satellite outdoor and indoor units, and power management and interface products. The company was founded by Kimihiko Imura, Curtis C. Ling, and Kishore V. Seendripu on September 25, 2003 and is headquartered in Carlsbad, CA.

MaxLinear Inc

MaxLinear is surging due to positive financial results and guidance that emphasize a strategic pivot into AI-driven data center infrastructure. The community is actively debating the sustainability of this sharp rally, with many traders discussing the potential for a continued momentum trade versus concerns that the stock may be overextended.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares is seeing explosive volume and intense debate as traders weigh the sector's relentless melt-up against potential signs of an overextended AI-driven bubble. While many investors are actively seeking entries into this leveraged inverse play, the community remains polarized between those calling for a historic blow-off top and those cautioning against the risks of volatility decay.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is seeing intense investor activity driven by a parabolic rally in the semiconductor sector, fueled by massive AI-driven infrastructure demand and consistent momentum that has kept the ETF trending higher. While many in the community are celebrating record gains and speculative targets, others are actively debating whether this represents a sustainable super-cycle or a dangerous bubble approaching a blow-off top.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Outlook Therapeutics Files FDA Resolution Request After Rejection For Vision Loss Drug

Outlook Therapeutics files FDA dispute on ONS-5010 after CRL citing effectiveness concerns; meeting with agency official set for April 2026.read more...

<ul class="summary-bullets"><li>The company stated that it intends to use the proceeds of the stock offering to meet its working capital requirements as well as other general corporate needs.</li><li>Last week, Outlook Therapeutics announced a new $18.4 million non-convertible unsecured note financing, stating that it will use a portion of the net proceeds to pay down an existing note.</li><li>In December 2025, the FDA issued a Complete Response Letter for ONS-5010 / LYTENAVA, saying it could not approve the treatment in its current form for wet AMD.</li></ul>Outlook Therapeutics Inc. (OTLK) shares plunged 32% in Tuesday’s pre-market trade after the company announced a proposed public offering of its common stock and accompanying warrants.Outlook Therapeutics announced the pricing of the public offering, stating that each share of common stock and the accompanying warrant are being sold at a combined price of $0.25. The company said it expects aggregate gross proceeds of $5 million and that the offering is expected to close on Wednesday, March 25, 2026.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/OTLK">Outlook Therapeutics</a> trended in the ‘extremely bearish’ territory, with message volumes at ‘high’ levels at the time of writing.<h2 class="st-heading-2">Why Did Outlook Therapeutics Announce The Offering?</h2>Outlook Therapeutics stated that it intends to use the proceeds of the stock offering to meet its working capital requirements as well as other general corporate needs.Last week, the company announced a new $18.4 million non-convertible unsecured note financing, stating that it will use a portion of the net proceeds to pay down an existing note.Earlier this month, Outlook Therapeutics provided an update with respect to a meeting with the U.S. Food and Drug Administration (FDA) regarding the company’s Biologics License Application for its treatment of wet age-related macular degeneration (wet AMD).In December 2025, the company said that the FDA issued a Complete Response Letter for its investigational treatment, ONS-5010 / LYTENAVA (bevacizumab-vikg), stating that it cannot approve the application in its present form for the treatment of wet AMD.The company said that if the FDA approves it, bevacizumab-vikg has the potential to be the first ophthalmic formulation of bevacizumab-vikg approved by the regulator for use in ophthalmology.Bevacizumab-vikg is a lab-made antibody that targets a protein called VEGF, which helps blood vessels grow. By blocking VEGF from binding to its receptors on blood vessel cells, the drug prevents the formation of new blood vessels.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Outlook Therapeutics’ proposed offering was&nbsp;criticized&nbsp;by a user on the platform, who called out the company for not giving a roadmap on how it intends to use the money, other than meeting its working capital and general corporate needs.<stembedurl>https://stocktwits.com/HarveySpecter20/message/648356634</stembedurl>Another user highlighted the lack of data on the uptake of the investigational treatment from patients.<stembedurl>https://stocktwits.com/updownsides/message/648355300</stembedurl><a href="https://stocktwits.com/symbol/OTLK">OTLK stock</a> is down 80% year-to-date and 79% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 16% over the past 12 months, while the iShares Micro-Cap ETF (IWC) is up 38%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fidelity-backs-elon-musk-tesla-spacex-terafab-project-datacenters-in-space/cZ3mK7PRI0u">Elon Musk's Joint Tesla, SpaceX Terafab Project Makes A 'Ton Of Sense', Says Investor Fidelity: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

Why Is OTLK Stock Falling Today?

Outlook Therapeutics announced the pricing of the public offering, stating that each share of common stock and the accompanying warrant are being sold at a combined price of $0.25.

Equity

Oncobiologics, Inc. (OTLK) Reports Q1 Loss, Misses Revenue Estimates

Oncobiologics (OTLK) delivered earnings and revenue surprises of -26.95% and -131.38%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Outlook Therapeutics Earnings Report: Q1 Overview

OTLK Stock Crashes 67% in a Week: Here's What You Need to Know

Outlook Therapeutics stock plunges 67% in a week after the FDA issues a third CRL rejecting its ONS-5010 BLA for wet AMD, again seeking confirmatory data.

Wall Street Zen Downgrades Oncobiologics (NASDAQ:OTLK) to Sell

Wall Street Zen downgraded Oncobiologics from a "hold" rating to a "sell" rating in a research report on Saturday...

Futures Blast Off On First Day Of 2026 With Europe, Asia At Records

Futures Blast Off On First Day Of 2026 With Europe, Asia At Records Stocks are set to break a four-day losing streak as markets start the new year with a bang across global markets, boosted by the...

<ul class="summary-bullets"><li>The FDA said it cannot approve the application in its present form for the treatment of wet age-related macular degeneration.</li><li>This marked the second rejection for Outlook’s drug for wet AMD treatment in less than six months.</li><li>The CEO said, “We are disappointed and disagree with this decision.</li></ul>Shares of Outlook Therapeutics (<a href="https://stocktwits.com/symbol/OTLK">OTLK</a>) slumped more than 60% on Friday after it failed to secure U.S. Food and Drug Administration approval for its drug Lytenava, which is intended to treat wet age-related macular degeneration (wet AMD), a chronic eye disorder.This marked the second rejection for Outlook’s drug for wet AMD treatment in less than six months. In August, the FDA declined to approve the drug, citing insufficient evidence of effectiveness, and recommended that the company submit additional data to support its application.In the Complete Response Letter (CRL), the FDA noted that the additional mechanistic and natural history data provided in the biologics license application (BLA) resubmission do not alter the previous review conclusion, adding that the FDA cannot approve the application in its present form for the treatment of wet age-related macular degeneration.“We are disappointed and disagree with this decision, but we remain fully committed to taking all necessary steps to receive approval in the United States,” Bob Jahr, Chief Executive Officer of Outlook Therapeutics, said in a statement.Lytenava has been granted marketing authorization by the European Commission in the EU and marketing authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the treatment of wet AMD.Age-related macular degeneration causes damage to the macula, a small area near the center of the retina, which is the part of the eye responsible for sharp, central vision. It is common among people aged 50 and older.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around OTLK trended in ‘extremely bullish’ territory amid ‘extremely high’ message volumes.<figure class="image"><img style="aspect-ratio:636/66;" src="https://news.stocktwits-cdn.com/otlk_3_PNG_39a4a7c8e1.webp" alt="Retail sentiment around OTLK trended in ‘extremely bullish’ territory amid ‘extremely high’ message volumes." width="636" height="66"></figure>However, the latest blow from the FDA has disappointed retail traders, with one user saying, “Even if they have money, they have proven approval is beyond their abilities.”<figure class="image"><img style="aspect-ratio:651/132;" src="https://news.stocktwits-cdn.com/OTLK_USER_1_PNG_ebd1b97a3d.webp" alt="latest blow from the FDA has disappointed retail traders, with one user saying, “Even if they have money, they have proven approval is beyond their abilities.”" width="651" height="132"></figure> The FDA disapproval prompted users to believe the company would do cost-cutting. With one user saying to expect the next PR to be cost-cutting and layoffs, followed by dilution, and yet another reverse split.<img src="https://news.stocktwits-cdn.com/otlk_4_PNG_f4b526073b.webp" alt="otlk 4.PNG">Shares of Outlook Therapeutics were down nearly 17% in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Outlook Therapeutics Tanks Over 60% On Another FDA Blow – Here’s How Retail Is Reacting 

OTLK Stock - The U.S. health regulatory agency, the FDA, rejected Outlook Therapeutics’ application for approval of its drug Lytenava, which is intended to treat wet AMD.

A Second FDA Rejection Sparked A Rout In Outlook Therapeutics Shares 

The U.S. health regulatory agency, the FDA, rejected Outlook Therapeutics’ application for approval of its drug Lytenava, which is intended to treat wet AMD.

Outlook Therapeutics Stock Sinks After FDA Rejects Eye Drug Again

Outlook Therapeutics' stock fell to a new low due to FDA rejection of its Lytenava filing for wet AMD. Efficacy evidence remains key issue.read more...

Outlook Therapeutics, Intelligent Bio Solutions And Other Big Stocks Moving Lower In Friday's Pre-Market Session

This account has been verified as an official OTLK representative.

Verified Account

Outlook Therapeutics

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Current Price	$0.3002
Prev Close	$0.2869
Open	$0.2853
Dividend Yield	0.00%
50-Day Moving Average	$0.3396
Beta	0.81
Avg. Volume	3.09M
PE Ratio	-0.26

52-Week High	$3.39
52-Week Low	$0.1611
Market Capitalization	$30.01M
EPS (Annual)	-$1.79
Price to Book	-0.48
Revenue Per Employee	$83,149.12

OTLK
Outlook Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OTLK News

OTLKOutlook Therapeutics Inc